Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies
/in International Publications, Newcastle Disease Virus /von 2017-12-20 / Trends Immunol. 2018 03;39(3):209-221Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2017-12-12 / Clin. Cancer Res. 2018 Feb;24(4):766-776Advances in immunotherapeutic research for glioma therapy
/in Dendritic Cells, Glioblastoma, International Publications /von 2017-12-05 / J. Neurol. 2018 Apr;265(4):741-756Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
/in International Publications, Pancreatic Cancer /von 2017-12-01 / Ann. Oncol. 2017 Dec;28(12):2950-2961
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution